Thursday May 23, 2019 Change -3.85% Price $21.25
Chart period: 2019-02-25 - 2019-05-23
VOLUME
Sell
TREND
Buy
MV LONG
Buy

MV SHORT
Buy

PIVOT
Sell

MACD
Sell

Will ZEAL stock price go up or down on Tue, 28 May 2019?

Predict

Zealand Pharma Forecast and Stock Analysis

Technical ZEAL stock analysis for Thursday May 23, 2019.

Buy candidate since 2019-05-20 Gain 4.89%
Shorts n/a
Insider % n/a
Institutional % 10.50%
Beta 1.20
ROA 55.92%
Price to book USD 3.95
P/E Ratio n/a
Next Earnings Date 2019-08-15


Zealand Pharma fell by -3.85% in the last day ( Thursday, 23rd May 2019 ) from $22.10 to $21.25 During day the stock fluctuated 0.85% from a day low at $21.25 to a day high of $21.43. The price has been going up and down for this period, and there has been a 4.53% gain for the last 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -50 348 shares and in total 4 287 shares bought and sold for approximately $91 098.80.

Quick summary:

  • 30 day high of the ZEAL stock price was $22.22 and low was $18.18.
  • 90 day high was $22.22 and low was $14.40.
  • 52 week high for the Zealand Pharma - $22.22 and low - $11.51.

Trend

Zealand Pharma lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 41.69% during the next 3 months and, with 90% probability hold a price between $28.75 and $32.71 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

Zealand Pharma holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $20.74 and $19.79. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Wednesday May 22, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 57 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Zealand Pharma finds support from accumulated volume at $21.05.

Support: $21.05 Price: $21.25 Resistance: $22.10

Risk

In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.

Our recommended stoploss: $20.06 (-5.62%) (This stock has low daily movements and this gives low risk. There is a sell signal from pivot top found 1 days ago.)

1.79 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Evaluation:

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Strong Buy Candidate to a Buy Candidate.

Buy Candidate Downgraded
ZEAL $21.25 ($-0.85 -3.85%)
ZEAL is down $0.85 today, but where's it headed in 2019?
Zacks Investment Research is releasing its prediction for ZEAL based on the 1-3 month system that more than doubles the S&P 500.

This report is free today for StockInvest.us readers.

Click here – the ZEAL analysis is free »

Will ZEAL stock price go up or down
on Tue, 28 May 2019?

Predict

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank